AIDS Reviews
Authors: Bright Forkuo-Forkuo, John Atanniba-Atanniba, Evelyn Y. Bonney-Bonney, Richard Donkor-Donkor, Reuben Adjei-Adjei, Mary Amoakoh-Coleman-Amoakoh-Coleman, Kwamena W. C. Sagoe-Sagoe, and George B. Kyei-Kyei.
Antiretroviral therapy (ART) keeps HIV under control, but it doesn’t cure it. The virus hides inside long-lived immune cells, forming a “reservoir” that restarts infection if treatment stops. When HIV enters a cell, it inserts its genetic material into the cell’s DNA. The location of that insertion, called the integration site, may affect whether the infected cell survives and multiplies.
The authors systematically reviewed 18 studies published between 2016 and 2025 on people taking ART. Most studies (61%) were done in the USA, and most involved HIV subtype B. Researchers mainly used a lab technique called ligation-mediated PCR to map where the virus had inserted.
Across studies, HIV mostly inserted inside genes (77% to 100% of sites), typically in non-coding stretches called introns, and often in the opposite direction to the gene’s own reading direction. Many insertions were in genes linked to cancer. Infected cells that had multiplied into large identical groups, called clones, often carried the virus in genes that control cell growth and immune signaling. This suggests the insertion site helps the cell, and the hidden virus inside it, persist for years.
The review also looked at three co-infections: cytomegalovirus, tuberculosis, and influenza. These didn’t clearly change where HIV inserted, but they were linked to more clonal expansion, probably through other mechanisms. The authors conclude that understanding what drives clone growth and survival will be important for designing treatments that target the HIV reservoir and move toward a cure.